Iovance Biotherapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Iovance Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $8.80. The average 1-year stock price forecast is 103.94% higher than the current stock price, while the lowest is $4.00 (-7.30%) and the highest is $14 (+224.45%).

Price Target: $8.80 (+103.94%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$4.00	$8.80	$9.50	$14
Change	-7.30%	+103.94%	+120.16%	+224.45%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	6	6	6	6	6	6
Buy	2	2	2	2	2	2
Hold	3	3	3	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	11	10	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Etzer Darout Barclays	Barclays	Buy Reiterates $11	Buy	Reiterates	$11	+154.92%	Jul 20, 2026
Salim Syed Mizuho Securities	Mizuho Securities	Buy Maintains $10	Buy	Maintains	$10	+131.75%	Jun 22, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $9	Buy	Reiterates	$9	+108.57%	Jun 4, 2026
Geulah Livshits Chardan Capital	Chardan Capital	Buy Reiterates $14	Buy	Reiterates	$14	+224.45%	May 8, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Maintains $5	Buy	Maintains	$5	+15.87%	May 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

362.34M

from 263.50M

37.51%

from 263.50M

Revenue Next Year

496.54M

from 362.34M

37.03%

from 362.34M

EPS This Year

-0.57

from -1.09

EPS Next Year

-0.32

from -0.57

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	1.19M	164.07M	263.50M	362.34M
Revenue Growth	-	-	-	13,698.99%	60.60%	37.51%
Gross Profit	-	-	156.00K	70.82M	90.32M	175.67M
Gross Margin	-	-	13.12%	43.17%	34.28%	48.48%
Operating Income	-342.70M	-398.88M	-460.56M	-395.28M	-398.21M	-253.23M
Net Income	-342.25M	-395.89M	-444.04M	-372.18M	-390.98M	-246.33M
EPS	-	-	-	-	-1.09	-0.57
Free Cash Flow	-129.35M	-173.54M	-211.47M	-198.76M	-162.42M	-213.00M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	369.8M
Avg	362.3M
Low	352.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	40.3%
Avg	37.5%
Low	33.6%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.46
Avg	-0.57
Low	-0.72

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-